Tempus AI Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tempus AI Inc reports strong Q3 results and strategic acquisitions

Tempus AI Inc (TEM) showcased robust performance in Q3 2024, driven by revenue growth and strategic acquisitions, positioning the company for continued success.
While challenges like organizational readiness and market dynamics exist, the company's disciplined approach and strong partnerships present opportunities for sustained growth.
Overall, Tempus' focus on innovation, customer-centricity, and financial discipline sets a solid foundation for future growth and market leadership in the healthcare technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, t.

Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests

HealthStream

BOSTON--(BUSINESS WIRE)-- #EmployeeEngagement--Lifeline Ambulance has successfully reduced operational costs by $460,000 and attrition by 58% by using Blink's employee engagement platform.

Lifeline Ambulance Saves $460,000 and Cuts Attrition by 58% with Blink's Employee Engagement Super-App

Ibotta Inc

PACS Group, Inc.

With the S&P 500 index trading near all-time highs, the initial public offering market has been robust. It's also not uncommon that quality IPO stocks remain under-the-radar for a while before surging higher as it catches analyst and investor attention.

3 Under-the-Radar IPO Stocks to Buy Before They Double

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company's multimodal data library. This research milestone includes published and/or acknowledged wor.

Tempus Surpasses 500 Research Publications

William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'

Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says

Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.

Why Wall Street Is Bullish on Healthcare Tech Stock Tempus AI

Tempus AI (NASDAQ:TEM), a provider of AI-enabled precision medicine, has been initiated with a 'buy' rating by Bank of America, which likes how the company combines a patient's molecular, clinical and other data to provide a new level of medical diagnostics.  There are other companies that provide similar molecular diagnostics – Guardant Health, Foundation Medicine, NeoGenomics (NASDAQ:NEO) for three – Tempus differs from most of them by adding layers of additional patient information such as MRI imaging data, patient records, as well as AI techniques such as neural networks, deep learning, and large language models.

AI-boosted medical diagnostics firm Tempus AI given 'buy' rating

A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics space.

Buy this healthcare company's stock because it's an AI play, analysts say

Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits.

Wall Street analysts bullish on genetic testing firm Tempus AI

TIMBERLAKE, N.C.--(BUSINESS WIRE)--The Call for Content for IASA's Xchange annual conference held June 8–10, 2025, in St. Louis, is now open.

IASA Opens Call for Content – June 2025 Annual Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company's PurISTSM algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurISTSM PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory develo.

American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM

Waystar Holding Corp

WEBTOON Entertainment Inc.

The market for initial public offerings (IPOs), featuring promising new IPOs, has rebounded strongly in 2024, with the number of offerings surpassing last year's total by 40%. The combined valuation of this year's IPOs has more than doubled compared to the previous year, sparking speculation about future public offerings.

IPO Watch: 3 New Stocks Worth a Strong Look

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced Diagnostic Laboratory Test (ADLT) status for Tempus' next-generation sequencing assay, xT CDx. xT CDx is the first Food and Drug Administration (FDA)-approved next-generation sequencing assay to perform matched normal sequence analysis to provide tumor mutation profiling for patients.

CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test

SoftBank Group Corp

Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to analyse personal medical data with artificial intelligence (AI) to come up with treatment recommendations.

SoftBank Group launches AI healthcare joint venture with Tempus AI

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Revere Payments helps fast-growing BigCommerce customers streamline payment processes and improve transaction security and enhance customer experience.

Revere Payments Named BigCommerce Preferred Technology Partner

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based notification software” and paves.

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies. As part of this collaboration, Tempus will develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hyper.

Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google.

Google Invested in This Hot New Artificial Intelligence (AI) Stock. Should You?

Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public.

Tempus IPO: Stock price watched today as AI health-tech company starts Nasdaq trading

One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital Solutions, respectively. One nanocap is currently scheduled to list in the week ahead, although some other small issuers may join the calendar throughout the week - Nova Minerals. Street research is expected for one company in the week ahead, and lock-up periods will be expiring for one company.

U.S. IPO Weekly Recap: Precision Medicine IPO Tempus AI Posts A Modest Gain In Its Debut

Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the losses incurred. With revenue growth slowing down dramatically and operating leverage coming to a standstill, I am leaning cautious about Tempus here.

Tempus AI: Healthcare AI Play Faces Some Challenges From The Start

Tempus, a genomic testing and data analysis company started by Eric Lefkosky, who previously founded Groupon, debuted on Nasdaq on Friday, rose about 15% on the opening

Tempus soars 15% on the first day of trading, demonstrating investor appetite for a health tech with a promise of AI

Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq.

Tempus AI Surges in Nasdaq Debut Following IPO

SoftBank Group-backed Tempus AI shares surged over 15% after its Nasdaq debut Friday, valuing the AI-driven genetic testing company at around $6.6 billion. The stock opened at $40 per share and rose to trade around $42.30 by midday, compared to the initial public offering (IPO) price of $37.

Tempus AI shares soar in Nasdaq debut

Shares of SoftBank Group-backed Tempus AI rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion.

News for Tempus AI Inc Stock (TEM)